Fabino Enterprises Ltd
Incorporated in 2011, Fabino Enterprises manufactures, markets, trades, and does packing of pharmaceutical and other wellness focused consumer products[1]
- Market Cap ₹ 5.67 Cr.
- Current Price ₹ 27.0
- High / Low ₹ 39.0 / 22.8
- Stock P/E
- Book Value ₹ 19.1
- Dividend Yield 0.00 %
- ROCE 5.61 %
- ROE 1.44 %
- Face Value ₹ 10.0
Pros
- Company's working capital requirements have reduced from 212 days to 104 days
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has low interest coverage ratio.
- Company has high debtors of 288 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Half Yearly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|
| 3.36 | 21.01 | 17.98 | 20.41 | |
| 3.33 | 20.89 | 17.87 | 20.65 | |
| Operating Profit | 0.03 | 0.12 | 0.11 | -0.24 |
| OPM % | 0.89% | 0.57% | 0.61% | -1.18% |
| 0.02 | 0.01 | 0.29 | 0.46 | |
| Interest | 0.01 | 0.04 | 0.13 | 0.16 |
| Depreciation | 0.03 | 0.04 | 0.08 | 0.10 |
| Profit before tax | 0.01 | 0.05 | 0.19 | -0.04 |
| Tax % | 0.00% | 20.00% | 68.42% | |
| 0.01 | 0.04 | 0.06 | -0.16 | |
| EPS in Rs | 0.05 | 0.19 | 0.29 | -0.76 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 64% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -700% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -4% |
| 1 Year: | -13% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 1% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|
| Equity Capital | 2.10 | 2.10 | 2.10 | 2.10 |
| Reserves | 2.01 | 2.04 | 2.10 | 1.91 |
| 0.41 | 1.27 | 1.79 | 1.76 | |
| 0.50 | 9.95 | 11.67 | 9.53 | |
| Total Liabilities | 5.02 | 15.36 | 17.66 | 15.30 |
| 0.15 | 0.34 | 0.55 | 0.42 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 |
| 4.87 | 15.02 | 17.11 | 14.88 | |
| Total Assets | 5.02 | 15.36 | 17.66 | 15.30 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|
| -0.68 | -0.77 | 0.12 | |
| -0.01 | -0.28 | -0.42 | |
| 0.34 | 0.86 | 0.48 | |
| Net Cash Flow | -0.35 | -0.18 | 0.18 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|
| Debtor Days | 274.84 | 219.07 | 287.66 |
| Inventory Days | 147.24 | 24.21 | 26.56 |
| Days Payable | 45.78 | 179.31 | 252.78 |
| Cash Conversion Cycle | 376.29 | 63.97 | 61.44 |
| Working Capital Days | 444.30 | 86.34 | 104.14 |
| ROCE % | 1.81% | 5.61% |
Documents
Announcements
-
Results- Financial Results For The Half Year Ended September 30, 2025
13 Nov - Unaudited H1 results to Sep 30, 2025: Consolidated revenue Rs690.90L; consolidated loss Rs18.59L; standalone loss Rs24.87L
-
Board Meeting Outcome for Outcome Of Board Meeting & Submission Of Unaudited Financial Results For Half Year Ended September 30, 2025
13 Nov - Board approved unaudited H1 results (Sep 30, 2025) — standalone loss Rs24.87L; consolidated loss Rs18.59L.
-
Board Meeting Intimation for Consideration And Approval Of Unaudited Financial Results (Standalone And Consolidated) For Half Year Ended September 30, 2025
10 Nov - Board meeting on Nov 13, 2025 to approve unaudited H1 financial results (Sept 30, 2025).
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
14 Oct - Certificate: Reg 74(5) non-applicable for quarter ended Sep 30, 2025 (dated Oct 10, 2025).
-
Closure of Trading Window
25 Sep - Trading window closed from 1 Oct 2025 until 48 hours after unaudited H1 (Sep 30, 2025) results announcement.
Business Overview:[1][2]
a) FEL is an ISO 9001:2015 pharmaceutical company located near the Delhi NCR region. It offers a wide range of allopathic and herbal products.
b) Company markets pharmaceutical formulation for domestic market and sells through own distribution network and sales force under
their own brand name
c) It gets Ayurvedic formulations manufactured through Loan Licensing facilities, Packing, Labelling etc.
d) Company exports wellness and FMCG products like Coffee, Malt powder, Protein powder, Hair shampoo which it also markets